RxDoctor Payments Data

Ward Irvin, PA

Physician Assistant · Liverpool, NYNPI 1831555747

Payments from drug & device makers

$3,229in general payments, 2019–2025

Across 170 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$678
  • AstraZeneca$437
  • Mallinckrodt Hospital Products Inc.$302
  • Boehringer Ingelheim$259
  • Takeda Pharmaceuticals U.S.A., Inc.$188
  • Verona Pharma, Inc.$159
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,14097%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,229 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$30,136
Medicare patients
197
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter442$329,017
Breztri AerosphereBudesonide/Glycopyr/Formoterol102$66,384
Breo ElliptaFluticasone/Vilanterol105$50,918
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$41,776
Dupixent SyringeDupilumab11$41,163
Pirfenidone12$22,689
Spiriva RespimatTiotropium Bromide20$18,225
SymbicortBudesonide/Formoterol Fumarate30$10,590
Tiotropium Bromide15$7,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$6,522
Albuterol Sulfate HfaAlbuterol Sulfate186$5,777
Advair HfaFluticasone Propion/Salmeterol15$5,475
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,438
Varenicline Tartrate11$4,629
Incruse ElliptaUmeclidinium Bromide13$4,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$678$426,159630 claims
AstraZenecaBreztri Aerosphere, Symbicort$437$76,974132 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$259$23,66332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →